Mariella Spalato Ceruso

List of Publications by Year
in descending order

20 papers	266 citations	840776 11 h-index	940533 16 g-index
20 all docs	20 docs citations	20 times ranked	480 citing authors

#	Article	IF	Citations
1	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clinical Cancer Research, 2022, 28, 1672-1679.	7.0	18
2	Implementing a Machine Learning Strategy to Predict Pathologic Response in Patients With Soft Tissue Sarcomas Treated With Neoadjuvant Chemotherapy. JCO Clinical Cancer Informatics, 2021, 5, 958-972.	2.1	3
3	Recent Advances in Desmoid Tumor Therapy. Cancers, 2020, 12, 2135.	3.7	18
4	Familial adenomatosis polyposisâ€“related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. ESMO Open, 2020, 5, e000604.	4.5	11
5	Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients. Chemotherapy, 2019, 64, 105-109.	1.6	14
6	Unexpected benefit from an â€˜oldâ€™ metronomic chemotherapy regimen in advanced chordoma. BMJ Case Reports, 2019, 12, e228728.	0.5	2
7	New frontiers in the medical management of gastrointestinal stromal tumours. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984194.	3.2	33
8	Advanced epithelioid haemangioendothelioma: Fever, pain, and pleural effusion predict a worse outcome.. Journal of Clinical Oncology, 2019, 37, e22540-e22540.	1.6	0
9	Use of cardioprotective dexrazoxane and myelotoxicity in anthracycline-treated soft tissue sarcoma patients.. Journal of Clinical Oncology, 2019, 37, 11053-11053.	1.6	0
10	Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. Oncology, 2018, 95, 1-7.	1.9	7
11	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879462.	3.2	27
12	Olaratumab: PDGFR-Î± inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. Critical Reviews in Oncology/Hematology, 2017, 118, 1-6.	4.4	16
13	Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.. Journal of Clinical Oncology, 2017, 35, 11038-11038.	1.6	0
14	Drug-induced hepatotoxicity in cancer patients - implication for treatment. Expert Opinion on Drug Safety, 2016, 15, 1219-1238.	2.4	52
15	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget, 2016, 7, 69412-69419.	1.8	17
16	Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. Scientific Reports, 2015, 5, 12077.	3.3	2
17	Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. Expert Review of Anticancer Therapy, 2015, 15, 971-976.	2.4	12
18	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	2.5	33

#	Article	IF	Citations
19	Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience.. Journal of Clinical Oncology, 2014, 32, 10515-10515.	1.6	1
20	Trabectedin-related liver toxicity in soft tissue sarcoma patients: Always a good reason to discontinue the treatment?. Journal of Clinical Oncology, 2014, 32, 10572-10572.	1.6	0